MétaCan
Menu
Back to cohort
Record W2205249602 · doi:10.1093/cid/civ963

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

2015· article· en· W2205249602 on OpenAlexfundno aff
L. Marije Hofstra, Nicolas Sauvageot, Jan Albert, Ivailo Alexiev, Féderico García, Daniel Struck, David van de Vijver, Birgitta Åsjö, Danail Beshkov, Suzie Coughlan, Diane Descamps, Algirdas Griškevičius, Osamah Hamouda, Andrzéj Horban, Marjo van Kasteren, Tatjana Kolupajeva, Leondios G. Kostrikis, Kirsi Liitsola, Marek Linka, Orna Mor, Claus Nielsen, Dan Oţelea, Dimitrios Paraskevis, Roger Paredes, Mario Poljak, Elisabeth Puchhammer‐Stöckl, Anders Sönnerborg, D Staneková, Maja Stanojević, Kristel Van Laethem, Maurizio Zazzi, Snježana Židovec Lepej, Charles A. Boucher, Jean-Claude Schmit, Annemarie M. J. Wensing

Bibliographic record

VenueClinical Infectious Diseases · 2015
Typearticle
Languageen
FieldMedicine
TopicHIV/AIDS drug development and treatment
Canadian institutionsnot available
FundersEuropean Regional Development FundAIDS FondetMinistry of Education and ScienceVetenskapsrådetFonds National de la Recherche LuxembourgMinistry of Health, British ColumbiaIstituto Superiore di SanitàResearch Promotion FoundationVlaamse regeringEuropean CommissionStyrelsen för Internationellt Utvecklingssamarbete
KeywordsMedicineDrug resistanceHuman immunodeficiency virus (HIV)Transmission (telecommunications)DrugSecond lineCurrent (fluid)VirologyFirst linePharmacologyInternal medicineMicrobiologyBiologyTelecommunications

Abstract

fetched live from OpenAlex

BACKGROUND: Numerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen. In addition to optimizing individual patient management, these baseline resistance data enable transmitted drug resistance (TDR) to be surveyed for public health purposes. The SPREAD program systematically collects data to gain insight into TDR occurring in Europe since 2001. METHODS: Demographic, clinical, and virological data from 4140 antiretroviral-naive human immunodeficiency virus (HIV)-infected individuals from 26 countries who were newly diagnosed between 2008 and 2010 were analyzed. Evidence of TDR was defined using the WHO list for surveillance of drug resistance mutations. Prevalence of TDR was assessed over time by comparing the results to SPREAD data from 2002 to 2007. Baseline susceptibility to antiretroviral drugs was predicted using the Stanford HIVdb program version 7.0. RESULTS: The overall prevalence of TDR did not change significantly over time and was 8.3% (95% confidence interval, 7.2%-9.5%) in 2008-2010. The most frequent indicators of TDR were nucleoside reverse transcriptase inhibitor (NRTI) mutations (4.5%), followed by nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.9%) and protease inhibitor mutations (2.0%). Baseline mutations were most predictive of reduced susceptibility to initial NNRTI-based regimens: 4.5% and 6.5% of patient isolates were predicted to have resistance to regimens containing efavirenz or rilpivirine, respectively, independent of current NRTI backbones. CONCLUSIONS: Although TDR was highest for NRTIs, the impact of baseline drug resistance patterns on susceptibility was largest for NNRTIs. The prevalence of TDR assessed by epidemiological surveys does not clearly indicate to what degree susceptibility to different drug classes is affected.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.151
Threshold uncertainty score0.388

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.027
GPT teacher head0.333
Teacher spread0.307 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations160
Published2015
Admission routes1
Has abstractyes

Explore more

Same venueClinical Infectious DiseasesSame topicHIV/AIDS drug development and treatmentFrench-language works237,207